What this is
- How it works
- How it works isn't classified yet
- Tested for
- Systemic Sclerosis, Rheumatoid Arthritis
- Main trialPhase 2/3
- “Systemic sclerosis (SSc), also called scleroderma, is a rare long-term autoimmune disease that causes the body to make too much collagen (scar tissue), leading to hard, thick skin and sometimes damage to organs such as the lungs, heart, kidneys, or digestive system. An autoimmune disease is a condition where the body's immune system, which normally protects against germs, mistakenly attacks its own healthy tissues and organs. The study has 2 parts. The main goal of Part 1 is to evaluate the safety and efficacy (how well the study treatment works) of ABBV-2294 (combination of ABBV-722 and…”In the company’s words, NCT07933211 on ClinicalTrials.gov
Other drugs for Systemic Sclerosis
- AnifrolumabAstraZeneca · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- BMS-986353Bristol Myers Squibb · Phase 3
- CABA-201Cabaletta Bio · Phase 2/3
- BelimumabGSK · Phase 3
- NerandomilastBoehringer Ingelheim · Phase 3
Coming up2
- Jul 2029Phase 2 trial completes · ClinicalTrials.gov
- Jun 2035Phase 2/3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovNew trial: none to Phase 2/3 · ClinicalTrials.gov NCT07933211
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | Jun 2035 | A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further. | |
| Phase 2Not yet recruiting | Jul 2029 | Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis | |
| Phase 1Completed | 23 Mar 2026 | A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants | |
| Phase 1Completed | 5 Jun 2026 | A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants | |
| Phase 1Completed | 25 Jun 2026 | A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants | |
| Phase 1Completed | 2 Jul 2026 | A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants | |
| Phase 1Completed | 21 Jul 2026 | A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults. | |
| Phase 1Completed | 3 Sep 2026 | A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026